Please ensure Javascript is enabled for purposes of website accessibility
tyler-laundon

Tyler Laundon

Chief Analyst, Cabot Small-Cap Confidential and Cabot Early Opportunities

Tyler Laundon is chief analyst of the limited-subscription advisory, Cabot Small-Cap Confidential and grand slam advisory Cabot Early Opportunities. He has spent his entire career managing, consulting and analyzing start-up and small-cap companies. His hands-on experience has taught Tyler that the development of a superior business model is the biggest factor in determining a company’s long-term success. Accordingly, his research focuses on assessing the viability of management’s growth strategies, trends in addressable markets and achievement of major developmental milestones.

Tyler’s small-cap portfolios favor a high allocation to stable, high growth companies, upon which he layers strategic purchases of higher risk, event-driven investments. He first began publishing his analysis of small-cap opportunities in 2009. Since 2012, he has led his subscribers into 10 doubles. Between 2012 and September, 2015 his small-cap recommendations generated cumulative returns of over 2,300%, including both winners and losers, and outperformed the Russell 2000 Index by an average of 28% per year.

Prior to joining Cabot, Tyler founded and operated a small business for 15 years. He then worked as a consultant for start-up technology companies, as well as Vermont’s largest health care institution. From 2009 to 2015, he was the chief analyst of growth stocks at Wyatt Investment Research, where his research spanned the full spectrum of the growth stock universe, from micro-cap start-ups to multi-national mega-caps.

Tyler holds a B.S. and MBA from The University of Vermont, where he graduated Valedictorian. He has been a long-time contributor to the Wall Street’s Best Investments, has been quoted by U.S. News & World Report, and has presented investing ideas and strategies for The Money Show and Bloomberg Markets LiveINSIGHTS.

From this author
Want to know how to find small-cap stocks? Here are my five rules for investing in these high-return, high-risk investments.
It’s been encouraging to see the market stabilize over the last two days (though yesterday was a crazy session).
Small-cap stocks will recover recent losses and be fine, eventually. It’s the uncertainty of what happens between now and then, and how long it takes, that has the potential to leave scars.
Today’s addition is a play on the growing shift toward healthier eating habits and nutritional supplements. It’s a small, U.S.-based natural foods grocery chain that’s growing, profitable, pays a dividend and has very little exposure to tariffs.

It offers considerable upside potential but also should have decent downside protection. In other words, a good stock for the current environment!
Warren Buffett can’t buy small-cap stocks any more, but here’s why you can and should. Keep reading to learn more investing like Buffett.
We are all trying to digest the substance of “Liberation Day” and better understand what lasting impact it will have on global trade, the market, stocks that we own and those we are considering buying.
We are all trying to digest the substance of “Liberation Day” and better understand what lasting impact it will have. Suffice to say, there are a lot of ways this could go. But one thing is for sure – we’re in uncharted territory.
Smart money has been looking beyond the U.S. at a wide range of global opportunities, and these six overseas small-cap ETFs are a good way to do the same.
The high hopes investors had for IPOs in 2025 have been fading of late, but despite the slowing pace of activity, there are still names worth watching.
Soleno Pharma (SLNO) Pops 40% on FDA Approval
The S&P 600 SmallCap Index is flat over the last week.

The upside move from the extreme oversold conditions that began two weeks ago has faded as the market grapples with tariff uncertainty.

Uncertainty will continue to linger even though Trump clarified part of his tariff plan last night through an executive order imposing permanent tariffs on autos not produced in the U.S.
The first quarter of 2025 has been interesting, to say the least. We wrap it up with the March Issue featuring names across the software, security, coffee chain, specialty metals and sports betting markets.

A few familiar faces, and a few new ones, should mean something for everybody. Details inside.
Today’s Weekly Update will be short and sweet. I am traveling back to the U.S. after a March break vacation with my wife, kids, parents and brother and sister’s families in the Bahamas.

The main market event of the week was yesterday’s FOMC meeting, which concluded with the Fed opting to hold rates steady. During his press conference Fed Chair Jerome Powell used the word “uncertainty” about a thousand times.
Just a quick reminder that, as per last week’s Special Bulletin, the March Issue of Cabot Early Opportunities will be published next Wednesday, March 26. Among the reasons for pushing the Issue back a week is that it will allow time for new portfolio additions to reflect today’s Fed decision to hold rates steady and the updated Summary of Economic projections (SEP), which implies a total of two 25-basis-point cuts this year.
This Market. March Issue Moved to the 26th
The market enjoyed a little bounce yesterday but is still working to find a level of support from which to mount an eventual recovery. This is a process, not an event. Nobody knows if we have reached that level yet.

We’ve been through these types of volatile markets many times in the past. While the drivers of the volatility are often different, one of the consistencies is that it is best to exercise patience and let new leaders show themselves. They always do.

In this case, the main drivers of the current market correction are Trump’s tariffs/trade war and massive disruptions in the federal government.
International markets, especially developed markets, have been outperforming the U.S. lately. It may be time to invest more abroad, and these six ETFs can help.
Sell Reddit (RDDT) and Second Half of FTAI Aviation (FTAI)
LandBridge (LB) Reports
Today’s addition is a profitable small-cap MedTech company specializing in products to treat peripheral nerve injuries.

Management has a number of growth-oriented irons in the fire. And I think the company could be an attractive acquisition target.

While the sock has been relatively stable in this increasingly volatile market, we’ll still start with a half-sized position, just in case.
Delcath (DCTH) reported before the bell this morning that Q4 revenue was $15.1 million (+2,701%) and adjusted EPS was $0.00. Revenue beat by $1.5 million (almost 11%). Gross margin was 86%.
Buy Second Half Reddit (RDDT)
It’s been a pretty ugly stretch lately, with numerous crashes in a number of growthy names. I’m far from confident that the selling is over, however, history has shown that a little buying when things seem bleak can pay off.
Sell Astera Labs (ALAB) and Cellebrite (CLBT)
FTAI Infrastructure (FIP), AvePoint (AVPT), Docebo (DCBO), Alkami (ALKT)
Finding promising small-cap stocks is only half the battle. Once you’ve found them, how do you manage them? These five steps can help make you a smarter small-cap investor.
FTAI Aviation (FTAI) Reports
While the broad market has stabilized a little over the last couple of days, we are still very much in a risk-off environment. As we all know, the market hates uncertainty. And we’re getting plenty of it these days

On-again, off-again tariff threats are the big story this week with Trump’s latest comments reiterating March 4 as the date for Mexico and Canada tariffs and April 2 as the date for reciprocal tariffs (tariffs that match those levied by other countries on U.S. exports), and an additional 10% tariff on China as of that date.
The IPO market has fallen quiet the last two weeks and deal size is light. Even so, IPOs spell opportunity, and these two recent IPOs are worth watching.